Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 13;6(6):695–703. doi: 10.1111/1759-7714.12239

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. Thoracic Cancer published by China Lung Oncology Group and Wiley Publishing Asia Pty Ltd.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Lapatinib and the estrogen receptor (ER) inhibitor fulvestran synergize against human epidermal growth factor receptor (HER)2-overexpressing xenografts. BT474 xenografts were established in female athymic nude mice. When tumors reached a volume ≥200 mm³, mice were randomly allocated to four treatment groups: vehicle (dimethyl sulfoxide [DMSO]) alone, lapatinib (100 mg/kg daily by orogastric gavage), fulvestran (5 mg/mice week by subcutaneous injection), or a combination. (a) Tumors were measured every three days. Mean tumor volume (n = 10) in mm³ ± standard error of the mean (SEM) for each treatment group is displayed. Mice tumors were stripped at the end of the treatment and weighed. The average weight ± SEM of mice in each treatment group is displayed. (bars: mean ± S.E.M.; asterisks: *, P < 0.05, compared with DMSO group; Student’s t-test). Ful, fulvestrant; Lap, lapatinib. , DMSO; , Ful; , Lap; , Lap+Ful.

Inline graphic — Lapatinib and the estrogen receptor (ER) inhibitor fulvestran synergize against human epidermal growth factor receptor (HER)2-overexpressing xenografts. BT474 xenografts were established in female athymic nude mice. When tumors reached a volume ≥200 mm³, mice were randomly allocated to four treatment groups: vehicle (dimethyl sulfoxide [DMSO]) alone, lapatinib (100 mg/kg daily by orogastric gavage), fulvestran (5 mg/mice week by subcutaneous injection), or a combination. (a) Tumors were measured every three days. Mean tumor volume (n = 10) in mm³ ± standard error of the mean (SEM) for each treatment group is displayed. Mice tumors were stripped at the end of the treatment and weighed. The average weight ± SEM of mice in each treatment group is displayed. (bars: mean ± S.E.M.; asterisks: *, P < 0.05, compared with DMSO group; Student’s t-test). Ful, fulvestrant; Lap, lapatinib. , DMSO; , Ful; , Lap; , Lap+Ful.